Abbott’s Amulet 360 Device Receives CE Mark for AFib Stroke Prevention

Abbott has received CE Mark approval for its next-generation Amulet 360™ Left Atrial Appendage (LAA) Occluder, aimed at reducing stroke risk in patients with atrial fibrillation (AFib). The device features design upgrades for better closure and adaptability to different LAA shapes. The first European procedures have been performed, with plans for wider distribution. This approval is backed by strong clinical data indicating efficacy and safety.